These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28535337)

  • 21. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
    Coelmont L; Hanoulle X; Chatterji U; Berger C; Snoeck J; Bobardt M; Lim P; Vliegen I; Paeshuyse J; Vuagniaux G; Vandamme AM; Bartenschlager R; Gallay P; Lippens G; Neyts J
    PLoS One; 2010 Oct; 5(10):e13687. PubMed ID: 21060866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
    Fernandes F; Poole DS; Hoover S; Middleton R; Andrei AC; Gerstner J; Striker R
    Hepatology; 2007 Oct; 46(4):1026-33. PubMed ID: 17600342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.
    Tsai YH; Kuang WF; Lu TY; Kao JH; Lai MY; Liu CJ; Chen PJ; Hwang LH
    J Hepatol; 2008 Dec; 49(6):899-907. PubMed ID: 18842320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
    Puyang X; Poulin DL; Mathy JE; Anderson LJ; Ma S; Fang Z; Zhu S; Lin K; Fujimoto R; Compton T; Wiedmann B
    Antimicrob Agents Chemother; 2010 May; 54(5):1981-7. PubMed ID: 20176894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B.
    Hanoulle X; Badillo A; Wieruszeski JM; Verdegem D; Landrieu I; Bartenschlager R; Penin F; Lippens G
    J Biol Chem; 2009 May; 284(20):13589-13601. PubMed ID: 19297321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ISGylation of Hepatitis C Virus NS5A Protein Promotes Viral RNA Replication via Recruitment of Cyclophilin A.
    Abe T; Minami N; Bawono RG; Matsui C; Deng L; Fukuhara T; Matsuura Y; Shoji I
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32727878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.
    Bagaglio S; Andolina A; Merli M; Uberti-Foppa C; Morsica G
    Viruses; 2016 Mar; 8(4):91. PubMed ID: 27023593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.
    McGivern DR; Masaki T; Williford S; Ingravallo P; Feng Z; Lahser F; Asante-Appiah E; Neddermann P; De Francesco R; Howe AY; Lemon SM
    Gastroenterology; 2014 Aug; 147(2):453-62.e7. PubMed ID: 24768676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.
    Nag A; Robotham JM; Tang H
    J Virol; 2012 Dec; 86(23):12616-24. PubMed ID: 22973029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded.
    Liang Y; Ye H; Kang CB; Yoon HS
    Biochemistry; 2007 Oct; 46(41):11550-8. PubMed ID: 17880107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation.
    Schenk C; Meyrath M; Warnken U; Schnölzer M; Mier W; Harak C; Lohmann V
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30258001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a.
    Bawono RG; Abe T; Shibata Y; Matsui C; Deng L; Shoji I
    Kobe J Med Sci; 2021 Sep; 67(2):E38-E47. PubMed ID: 34795154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
    Esser-Nobis K; Romero-Brey I; Ganten TM; Gouttenoire J; Harak C; Klein R; Schemmer P; Binder M; Schnitzler P; Moradpour D; Bartenschlager R; Polyak SJ; Stremmel W; Penin F; Eisenbach C; Lohmann V
    Hepatology; 2013 Mar; 57(3):953-63. PubMed ID: 23322644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.